Talasa NF (Butamirate citrate) may be used to help with symptomatic relief from specific types of cough, supporting the moderation of the frequency and intensity of disruptive episodes. It is generally applied to symptoms that interfere with daily functioning.

The medication is generally applied across therapeutic contexts where supportive symptom management is appropriate. It may be applied in conditions characterized by periods of heightened symptoms, including: the irritating, non-productive dry cough associated with acute episodes, and in clinical scenarios like preoperative and postoperative periods.

“This symptomatic support may assist in easing the overall burden of persistent, unproductive coughing.”

The medication is considered relevant in contexts involving heightened systemic burden, such as nocturnal coughing, where its use can contribute to improved comfort and may help patients cope more steadily with difficult episodes.

---

Quick Fact: Relief for Dry, Irritating Cough

Domain	Focus	Benefit
Symptom Type	Irritating, non-productive cough, throat tickle	Contributes to easing day-to-day comfort
Contexts	Acute respiratory episodes, post-procedural	Supports symptom management during difficult phases
Key Action	Moderates frequency and intensity of spasms	Assists with maintaining functional stability (e.g., sleep)

Regulatory References

1. Philippine FDA Verified Product Insert

Who Can and Cannot Use Talasa NF?

This section outlines the official population eligibility and non-eligibility rules for Talasa NF (Butamirate citrate) as defined in government regulatory labeling.

---

Eligibility Scope

Populations for whom use is allowed (as stated in label):

• Adults and Adolescents (age 12 and older).
• Children starting from 3 or 4 years of age, depending on the formulation and regulatory jurisdiction.

Populations for whom use is not recommended (if applicable):

• Individuals during Breastfeeding (data on excretion in human milk is lacking).
• Pregnant individuals during the First Trimester.
• Patients taking Expectorants concurrently.

Populations for whom use is contraindicated:

• Children under 3 years of age.
• Individuals with known hypersensitivity to Butamirate citrate or any excipient.
• Patients with hereditary problems of fructose intolerance.

---

Age-Related Eligibility Rules

• Absolute Pediatric Exclusion: Use is contraindicated in children under 3 years of age.
• Geriatric Use: Regulatory documents note that specific use in the elderly has generally not been investigated.

Condition-Specific Eligibility Rules

• Organ Function Impairment: Use requires caution in patients with renal or hepatic impairment, as official data is lacking for these populations.
• Concomitant Medication: The simultaneous administration of expectorants must be avoided.

Pregnancy and Lactation Eligibility Status

• Pregnancy (First Trimester): Must not be used.
• Pregnancy (Second and Third Trimesters): Use is conditional; must be administered with caution and only if absolutely necessary.

---

Eligibility Classifications (High-Level)

Eligibility severity classification (as defined in official documents):

• Contraindicated (e.g., Children < 3 years).
• Not Recommended (e.g., Lactation, First Trimester).
• Use with Caution (e.g., Hepatic/Renal Impairment).

Connection to the overall eligibility profile: Regulatory documents establish the eligibility profile through absolute prohibitions related to age and allergy, while imposing restrictions or requirements for caution on individuals who are pregnant, breastfeeding, or have pre-existing organ impairment. This structure classifies users into allowed, restricted, or prohibited categories based on formal, label-based constraints.

Talasa NF Interactions with other medicines and products

Talasa NF (containing the active substance talazoparib) can interact with several other medicines and products, potentially affecting how it works or increasing the risk of side effects. It is essential to inform your healthcare provider about all prescription and non-prescription drugs, vitamins, herbal supplements, and foods you are currently using.

Significant Drug Interactions

Type of Interacting Medicine	Specific Examples (Not an exhaustive list)	Potential Effect
P-glycoprotein (P-gp) Inhibitors	Itraconazole, Amiodarone, Carvedilol, Clarithromycin, Verapamil	Can increase the concentration of Talasa NF in the blood, raising the risk of adverse reactions, particularly blood-related toxicities (e.g., anemia).
BCRP Inhibitors	Ciclosporin, Eltrombopag	May increase the blood levels of Talasa NF, leading to higher exposure and potentially increased side effects.

If co-administration with P-gp inhibitors is unavoidable, your doctor may need to adjust the dosage of Talasa NF. Similarly, monitor closely for increased side effects when taking BCRP inhibitors. Always follow your physician's instructions regarding dose adjustments and monitoring.

Other Interactions

While specific interactions with food or alcohol are generally not considered significant, as a precaution, patients should discuss the consumption of grapefruit or grapefruit juice with their doctor, as it may affect the metabolism of certain medications. This section does not include all possible interactions, and continuous review of your medication list by a healthcare professional is crucial during treatment with Talasa NF.

Molecular Mechanism: Chelating Free Iron

Talasa NF functions as a tridentate chelator that acts on excess ferric iron (mathbfFe^3+) found in the blood and tissues, forming a stable, water-soluble complex. This targeted sequestration of the mineral initiates the clearance of the iron-drug complex via the excretory pathways.

---

Physiological Pathway: Modulating Iron Excretion

The primary physiological pathway affected is iron homeostasis. By making the iron ion water-soluble via chelation, the drug is conducive to its excretion from the body, primarily through the urine. The continuous clearance results in a shift toward a negative iron flux.

---

Mechanistic Consequence: Modulating Oxidative Stress

A key downstream effect of this mechanism is the decrease in oxidative stress. By removing the pro-oxidant catalyst (excess iron), the drug prevents the iron-catalyzed formation of harmful reactive oxygen species (ROS). This action assists in modulating the impact of iron-catalyzed toxicity on key organs.

How to Use Talasa NF

The administration of Talasa NF (Butamirate citrate) is guided by instructions that specify the approved route, dosage forms, and administration schedule. The medicine is strictly for oral administration and is available as a syrup, drops, and sustained-release (SR) tablet.

---

Official Dosing and Schedule

Dosage is determined by the patient's age and the specific formulation used. The frequency pattern for liquid forms is generally multiple times daily, while the SR tablets are taken less frequently to align with their prolonged release profile.

Age Group	Formulation	Labeled Dosing Regimen	Frequency / Interval
Adults	50 mg SR Tablet	50 mg per dose	2 to 3 times daily (every 8–12 hours)
Adults	Syrup	15 mL (22.5 mg) per dose	Up to 4 times daily
Children (6–12 yrs)	Syrup	10 mL (15 mg) per dose	3 times daily
Children (3–6 yrs)	Syrup	5 mL (7.5 mg) per dose	3 times daily

---

Administration Requirements

Official instructions impose specific constraints regarding the duration and method of intake. Treatment is generally short-term and often limited to a maximum of one week unless otherwise advised by a physician.

• Liquid Forms: The exact dose, which is specified in milliliters (mL), must be measured using a calibrated measuring device (such as a cup or dropper) to ensure accuracy. Doses are typically taken before meals.
• SR Tablets: Sustained-release tablets must be swallowed whole to preserve the intended release profile; they must not be crushed or chewed.
• Missed Dose: If a dose is missed, guidance instructs the patient to skip the missed dose and take the next dose at the regularly scheduled time, avoiding any attempt to compensate by doubling the amount.

Talasa NF: Recent Clinical Evidence

---

Evidence for Symptomatic Relief of Acute, Dry Cough

Research examined Butamirate citrate in the context of irritative, non-productive coughs associated with acute or disruptive episodes linked to seasonal respiratory issues. Studies explored this area primarily through short-term, double-blind Randomized Controlled Trials (RCTs) and systematic reviews. The primary populations was studied for this indication were Adults, Children (aged 3 and older), and Geriatric patients experiencing dry coughs. Researchers monitored measures like cough frequency, severity scores, and the impact on night-time sleep. Scientific reviews note that some of the foundational data may be characterized as reflective of the standards of earlier research.

Research in Specific Clinical Contexts

Butamirate citrate was evaluated in specific therapeutic situations where cough suppression may be a therapeutic consideration. This includes conditions involving periods of heightened symptoms, such as cough observed in palliative care settings and in pre- and post-operative environments. Scientific sources indicate that the available evidence for this application is limited, and findings were mixed when aggregated across studies.

Scope of Follow-up and Long-Term Data

The majority of clinical research was observed in trials exploring short-term symptom changes over periods typically limited to between three and seven days. Scientific sources indicate that long-term effects are not fully established for this medicine. The research has not focused on maintenance data or what happens to patients over extended periods. Therefore, there is limited information for long-term outcomes.

Study Quality and Scientific Limitations

Systematic scientific reviews have explored the quality of the existing evidence. These reviews indicate that evidence quality varies across studies, with some aggregated studies characterized by low methodological quality and a noted risk of bias. This means that while a history of research exists, certainty remains low when drawing broad, definitive conclusions based on the full scope of the evidence.

Common questions about Talasa NF (FAQ)

---

Q: How long does it typically take to see any effect from Talasa NF?

Official pharmacokinetic information describes how the drug is handled by the body. The drug is rapidly and completely absorbed. Studies indicate that the concentration of the active substance in the blood reaches its highest point around 1.5 hours after a single dose.

---

Q: How is Talasa NF thought to be absorbed by the body?

According to official regulatory information regarding the drug's properties, Talasa NF is absorbed quickly and thoroughly following oral administration.

---

Q: Does Talasa NF contain any common allergens like gluten or lactose?

Regulatory labeling lists all inactive ingredients, or excipients, used in the medicine's formulation. Since the exact composition can vary between different formulations and manufacturers, specific excipients, such as lactose or starch components, should be confirmed by reviewing the product information for the exact formulation a person is using.

---

Q: Can I take Talasa NF if I'm already taking daily vitamins or supplements?

Official documents detailing drug interactions focus on specific medicines that may affect the drug's concentration in the blood. While interactions with basic daily vitamins are generally not specified, official patient information states that a healthcare provider should be made aware of all prescription drugs, non-prescription medicines, vitamins, and herbal supplements that are currently being taken.

---

Q: Does Talasa NF interact with common cold or flu medicines?

Official product information states that concurrent use of Talasa NF with expectorants (medicines that help thin mucus) is not recommended. This is because combining them may potentially lead to a build-up of mucus in the respiratory passages. Interactions with other common cold and flu relief medicines are not generally specified.

---

Q: Is it normal for Talasa NF to cause mild stomach upset when first starting?

Official documentation indicates that gastrointestinal effects, such as nausea and diarrhea, are documented as infrequent adverse reactions. However, the available product information does not specify if these symptoms are more common during the first few days of starting the medicine compared to later in the treatment course.

---

Q: What is the shelf life of Talasa NF before it expires?

The official shelf life for sealed syrup formulations is often specified as being up to 36 months. However, once the product is opened, the usable duration may be shorter, depending on the specific product instructions. For certain liquid forms, the shelf life after the first opening is specified as six months.

---

Q: Can taking Talasa NF affect my sleep patterns?

Official product information indicates that drowsiness and dizziness are documented as adverse reactions. Regulatory documents state that caution is required when performing activities that demand mental focus due to the potential for drowsiness and dizziness.

---

Q: Is Talasa NF the type of medicine that needs to build up in my system?

Official pharmacokinetic studies show that the drug's concentration in the bloodstream acts in a linear fashion after repeated use. This indicates that, based on regulatory documentation, the drug is not expected to accumulate significantly in the system.

---

Q: What should I do if I notice a side effect mentioned in the official paperwork?

Regulatory documentation emphasizes that the reporting of any suspected adverse reactions after a medicine has been approved is important for ongoing safety monitoring.

---

Q: Is Talasa NF known to interact with birth control pills?

Regulatory safety information advises that, due to the drug’s effects on a fetus or newborn not being fully established, women of childbearing potential who require the medicine should use an appropriate method of contraception. This requirement reflects the need for precautions regarding potential conception while using the medicine.

---

Q: What kinds of symptoms might suggest I should not be taking Talasa NF?

Official documentation states that the medicine is contraindicated in cases of known hypersensitivity (allergic reaction) to the active substance or any of the inactive ingredients. Therefore, symptoms such as hives or an itchy rash (urticaria), which are known adverse reactions, would be indicators of this sensitivity.

---

Q: Does Talasa NF contain any sugars or artificial sweeteners?

The official warnings for the medicinal product note that the liquid forms contain Sorbitol. Because of this, the medicine is contraindicated for use in patients who have a rare hereditary problem known as fructose intolerance.

Official Storage and Disposal Requirements

Storage and disposal instructions for Talasa NF (Butamirate citrate) are strictly defined in regulatory labeling to ensure product quality and public safety.

Storage & Disposal Scope	Official Regulatory Requirement
Temperature Requirements	Store the medicine at temperatures not exceeding 30 C or below 25 C in cool, dry conditions.
Handling Requirements	The product must be protected from light.
Stability After Opening	Do not use the medicine after the expiry date. For some syrup formulations, the shelf life after first opening may be 6 months.
Child Protection	The product must be kept out of the sight and reach of children.
Disposal	Do not dispose of the medicine via wastewater or household waste. Unused or expired product must be discarded in accordance with local requirements.

These official statements mandate specific environmental controls, primarily protection from excessive heat and light, and a dedicated storage place away from children. The disposal process is governed by environmental restrictions that prohibit flushing or throwing the product into the trash.